NEAL SHIV CHAWLA
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology SANTA MONICA, CA NPI 1669906665
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology CA Aadi Bioscience, Inc. All categories
General Payments — all program years on this page
$1,302.82
- Category: General Payments
- Program years: PY2024
- Record count: 45
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $1,302.82 across 45 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,302.82 | 45 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Aadi Bioscience, Inc. | $222.46 | 4 |
| E.R. Squibb & Sons, L.L.C. | $109.57 | 5 |
| Daiichi Sankyo Inc. | $84.62 | 3 |
| Gilead Sciences, Inc. | $80.77 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $75.89 | 2 |
| Astellas Pharma US Inc | $70.65 | 3 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $58.18 | 2 |
| Lilly USA, LLC | $56.94 | 2 |
| Incyte Corporation | $55.42 | 2 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $51.24 | 2 |
| Ipsen Biopharmaceuticals, Inc | $50.02 | 2 |
| Merck Sharp & Dohme Corporation | $46.32 | 2 |
| SpringWorks Therapeutics, Inc. | $42.86 | 2 |
| Coherus Biosciences Inc. | $39.01 | 2 |
| Karyopharm Therapeutics Inc. | $34.35 | 1 |
| PROGENICS PHARMACEUTICALS, INC. | $28.88 | 1 |
| Agios Pharmaceuticals, Inc. | $28.82 | 1 |
| Deciphera Pharmaceuticals Inc. | $24.02 | 1 |
| ABBVIE INC. | $23.37 | 1 |
| Acerta Pharma LLC | $23.18 | 1 |
| Celgene Corporation | $22.74 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $21.81 | 1 |
| Helsinn Therapeutics (U.S.), Inc. | $20.16 | 1 |
| SOBI, INC | $16.77 | 1 |
| ADC Therapeutics America, Inc. | $14.77 | 1 |
By program year
| Program year | Amount | Records |
|---|---|---|
| 2024 | $1,302.82 | 45 |
Records — PY2024 (45)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.